Advertisement
Screener

Tyra Biosciences, Inc. (TYRA) Graph

TYRA Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Research and development $39.20M; Selling, general and administrative (m); Operating expenses $49.00M; Net income -$45.56M.
  • 2026-03-31: Research and development $33.47M; Selling, general and administrative (m); Operating expenses $42.00M; Net income -$39.30M.
  • 2025-12-31: Research and development $28.19M*; Selling, general and administrative (m); Operating expenses $36.52M*; Net income -$33.83M*.
  • 2025-09-30: Research and development $25.47M; Selling, general and administrative (m); Operating expenses $32.94M; Net income -$29.87M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endResearch and developmentSelling, general and administrativeOperating expensesNet income
2026-06-30$39.20M(m)$49.00M-$45.56M
2026-03-31$33.47M(m)$42.00M-$39.30M
2025-12-31$28.19M*(m)$36.52M*-$33.83M*
2025-09-30$25.47M(m)$32.94M-$29.87M
2025-06-30$24.31M(m)$31.45M-$28.10M
2025-03-31$24.96M(m)$31.85M-$28.15M
2024-09-30$22.70M(m)$28.60M-$24.02M
2024-06-30$18.00M(m)$23.53M-$18.70M
2024-03-31$17.20M(m)$22.32M-$18.19M
2023-09-30$19.27M$0.00$23.96M-$21.15M
2023-06-30$12.16M$0.00$16.01M-$13.27M
2023-03-31$10.41M(m)$14.33M-$11.88M
2022-09-30$10.91M$173.00K$13.64M-$12.51M
2022-06-30$12.05M$186.00K$15.43M-$15.10M
2022-03-31$9.64M(m)$14.83M-$14.83M
2021-09-30$5.48M(m)$6.64M-$6.64M
2021-06-30$4.38M(m)$5.51M-$5.51M
2021-03-31$3.52M(m)$4.21M-$4.21M
2020-12-31(m)(m)(m)-$3.69M
2020-09-30$1.86M(m)$2.33M-$2.34M
2020-06-30(m)(m)(m)-$1.84M
2020-03-31(m)(m)(m)-$1.47M

Revenue and expense 6 month

Period endResearch and developmentSelling, general and administrativeOperating expensesNet income
2026-06-30$72.67M(m)$91.00M-$84.86M
2025-06-30$49.27M(m)$63.30M-$56.24M
2024-06-30$35.20M(m)$45.85M-$36.89M
2023-06-30$22.57M$0.00$30.35M-$25.15M
2022-06-30$21.69M$396.00K$30.26M-$29.92M
2021-06-30$7.90M(m)$9.72M-$9.72M

Revenue and expense 9 month

Period endResearch and developmentSelling, general and administrativeOperating expensesNet income
2025-09-30$74.74M(m)$96.25M-$86.11M
2024-09-30$57.90M(m)$74.43M-$60.91M
2023-09-30$41.84M$0.00$54.31M-$46.30M
2022-09-30$32.61M$570.00K$43.91M-$42.43M
2021-09-30$13.39M(m)$16.36M-$16.36M
2020-09-30$4.28M(m)$5.62M-$5.65M

Revenue and expense 12 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-12-31$102.93M$132.76M$0.00-$119.95M
2024-12-31$80.08M$104.18M$0.00-$86.48M
2023-12-31$62.52M$79.94M$0.00-$69.13M
2022-12-31$43.01M$58.93M$2.00K-$55.33M
2021-12-31$20.64M$26.29M$1.00K-$26.29M
2020-12-31$7.20M$9.30M$1.00K-$9.34M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kardigan, Inc. (KARD)United States$1.346B
Bicara Therapeutics Inc. (BCAX)United States$1.309B-10.55
Oric Pharmaceuticals, Inc. (ORIC)United States$1.367B-8.00
First Tracks Biotherapeutics, Inc. (TRAX)United States$1.280B
Avalyn Pharma Inc. (AVLN)United States$1.267B
Damora Therapeutics, Inc. (DMRA)$1.250B-6.10
HARROW, INC. (HROW)United States$1.240B-42.77
OPKO HEALTH, INC. (OPK)United States$1.220B-15.59
LB PHARMACEUTICALS INC (LBRX)United States$1.220B-10.87
OMEROS CORP (OMER)United States$1.456B5.50